STK26

Serine/threonine-protein kinase 26 · Q9P289 · STK26 on Sugi Atlas →

6,233 patent compounds predicted against STK26, 4,596 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL580797	0.47	2/20
SCHEMBL1074134	0.41	2/20
SCHEMBL1074138	0.41	2/20
Hydrochloric Acid (SCHEMBL1073441)	0.41	2/20
SCHEMBL415996	0.38	2/20
Trifluoroacetic Acid (SCHEMBL1071674)	0.37	2/20
SCHEMBL1073905	0.37	2/20
Trifluoroacetic Acid (SCHEMBL1072466)	0.36	2/20
SCHEMBL1074034	0.36	2/20
Hydrochloric Acid (SCHEMBL1073613)	0.35	2/20
SCHEMBL1074434	0.33	2/20
Trifluoroacetic Acid (SCHEMBL1073656)	0.33	2/20
Amg-900 (SCHEMBL503564)	1.00	1/20
SCHEMBL581178	0.84	1/20
SCHEMBL580354	0.84	1/20
SCHEMBL62562	0.82	1/20
SCHEMBL581542	0.82	1/20
SCHEMBL581159	0.81	1/20
SCHEMBL580342	0.80	1/20
SCHEMBL740790	0.78	1/20

Clinical trials — most relevant to STK26 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Efficacy and Safety of Deucravacitinib in Takayasu's Arteritis	PHASE4	NOT_YET_RECRUITING
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
Signal TrAnsduction Pathway Activity Analysis in OVarian cancER	PHASE2/PHASE3	RECRUITING
Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations	PHASE2	COMPLETED
Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)	PHASE2	COMPLETED
Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma	PHASE2	COMPLETED
Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE)	PHASE1/PHASE2	NOT_YET_RECRUITING
Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors	PHASE2	RECRUITING
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer	PHASE2	COMPLETED
PKC412 and 5-Azacytidine	PHASE1/PHASE2	COMPLETED
Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer	PHASE1	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
A Dose-Escalation Study of SPYK04 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).	PHASE1	ACTIVE_NOT_RECRUITING
TSL2109 Capsules in Advanced Solid Tumor Patients: Safety, Tolerability, PK and Preliminary Efficacy	PHASE1	RECRUITING
A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212	PHASE1	COMPLETED
Nilotinib in Huntington's Disease	PHASE1	UNKNOWN
New Genes in the Carcinogenesis of Colorectal Cancer	nan	UNKNOWN
Association Between Intakes of Protein, Calcium and Milk With Gene Expression and Linear Growth of School Aged Children	nan	COMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
NTRK 1,2,3 Rearrangements in Patients With Solid Tumors	nan	ACTIVE_NOT_RECRUITING
Identification of Novel Targetable Kinases in SR-a GvHD	nan	COMPLETED
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA	nan	RECRUITING
Study Of Real-World Evidence In Patients Treated With Palbociclib During a 2.5 Years Follow-Up Period	nan	UNKNOWN
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma	nan	COMPLETED
Protein Intake and Step Reduction in Older Adults	nan	COMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
A Retrospective Clinical Records Review of Patients Diagnosed With Gastrointestinal Stromal Tumour at Two Tertiary Institutes in Singapore	nan	COMPLETED
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)	nan	COMPLETED
Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a STK26 binder may also engage these)

Protein	Name	Similarity
Q99JT2	—	1.000	Q99JT2 →
Q99KH8	—	1.000	Q99KH8 →
STK24	Serine/threonine-protein kinase 24	1.000	landscape →
B0LT89	—	0.996	B0LT89 →
O61125	—	0.994	O61125 →
STK25	Serine/threonine-protein kinase 25	0.993	landscape →
PAK3	Serine/threonine-protein kinase PAK 3	0.992	landscape →
Q3SWY6	—	0.992	Q3SWY6 →
P35465	—	0.992	P35465 →
Q9Z2W1	—	0.992	Q9Z2W1 →
PAK2	Serine/threonine-protein kinase PAK 2	0.991	landscape →
Q08E52	—	0.991	Q08E52 →
O88643	—	0.991	O88643 →
Q8AXB4	—	0.991	Q8AXB4 →
A4K2M3	—	0.991	A4K2M3 →
Q9NB31	—	0.990	Q9NB31 →
Q4KSH7	—	0.990	Q4KSH7 →
A4K2Y1	—	0.990	A4K2Y1 →
Q7YQL3	—	0.990	Q7YQL3 →
Q7YQL4	—	0.989	Q7YQL4 →
Q9JI10	—	0.989	Q9JI10 →
MAP2K7	Dual specificity mitogen-activated protein kinase kinase 7	0.989	landscape →
Q8CIN4	—	0.989	Q8CIN4 →
Q5E9L6	—	0.989	Q5E9L6 →
A4K2Q5	—	0.988	A4K2Q5 →
A4K2W5	—	0.988	A4K2W5 →
STK4	Serine/threonine-protein kinase 4	0.988	landscape →
P13234	—	0.988	P13234 →
Q9FJV0	—	0.988	Q9FJV0 →
A4K2T0	—	0.988	A4K2T0 →